CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies
CEVEC Pharmaceuticals announced the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized Expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community. Life Technologies will pay CEVEC a signing fee and various milestone payments and royalties on sales of the future products. Further details of the agreement were not disclosed. CEVEC will continue to expand its global license business of the CAP® and CAP-T® technologies for commercial use and industrial development purposes.
CEVEC’s transient CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns.
Life Technologies combines CEVEC’s proprietary protein expression system based on CAP cells with its tailored protein expression product portfolio (media, transfection reagents etc.) to enable research scientists worldwide to achieve highest yield and quality protein expression.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Cells help viruses during cell entry
Supply chains key to Life Sciences transformation - The change is urgent as the sector needs to catch-up in adopting digitalization
Dianax receives €2M grant from EU - The EU funds will allow Dianax to accelerate development and move into industrial phase
Tuberculosis vaccines, drugs and diagnostics under development expected to have major impact one the disease
Study ends debate over role of steroids in treating septic shock
Chris Beaver joins Pharmanet as Director, Immunochemistry Services
'Dry eye' linked to chronic pain syndromes
New stem cell strategy aids heart regeneration after heart attack

Novel tools for biomedical applications: Bacterial magnetic nanoparticles - Developed and optimised a process for the isolation and purification of these particles from bacterial cells
A decade of refinements in marrow and stem cell transplantation improves long-term survival of blood cancers

Coat of proteins makes viruses more infectious and links them to Alzheimer's disease
